Previous 10 | Next 10 |
2023-04-05 23:47:05 ET Summary Pulmonx has an FDA-approved technology to treat severe emphysema, which is estimated to be a $12 billion market. However, adoption rate has been slow and the company has been burning cash. After more than doubling in the past few months, I recomm...
Shares of Pulmonx Corporation (NASDAQ: LUNG) were up 10.9% for the week as of Friday afternoon after being up as much as 13%, according to data provided by S&P Global Market Intelligence . The healthcare company, which focuses on providing minimally invasive interventional pul...
Pulmonx Corporation. (LUNG) Q4 2022 Earnings Conference Call February 22, 2023, 04:30 PM ET Company Participants Laine Morgan - Investor Relations, Gilmartin Group Glen French - President and Chief Executive Officer Derrick Sung - Chief Financial Officer Conferen...
Pulmonx press release ( NASDAQ: LUNG ): Q4 GAAP EPS of -$0.38 beats by $0.04 . Revenue of $15.43M (+12.6% Y/Y) beats by $1.45M . Added 17 new U.S. treatment centers for Zephyr Valves in the fourth quarter 2022, increasing total U.S. treatment center...
REDWOOD CITY, Calif., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the fourth quarter and full year of 2022 ended December 31...
REDWOOD CITY, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in a fireside chat at the Citi 2023 Healthcare Conferenc...
Summary Pulmonx Corporation repriced >112% off its 52-week lows from November to date. We sought to examine the price action and make a practical assessment of its potential to extend further. Key trend indicators and price structure analysis sees demand tightening and yet to pus...
REDWOOD CITY, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for lung disease, today announced that it will release financial results for the fourth quarter and full year of 2022 after the cl...
Pulmonx ( NASDAQ: LUNG ) Form SC 13G filing shows a total 5.3% stake of Point72 Asset Management in the company. Number of shares owned by Point72 Asset Management is ~1.96M. The stock has par value of $0.001 per share. For further details see: Point72 Asset Ma...
Pulmonx Highlights 2022 Partnership with Lung Association Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”), a global leader in minimally invasive treatments for severe lung disease, has partnered with American Lung Association to provide education to patients and providers...
News, Short Squeeze, Breakout and More Instantly...
2024-06-23 01:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
A look at the top 10 most actives in the United States Allarity Therapeutics Inc. (ALLR) rose 97.8% to $2.71 on volume of 44,141,232 shares Faraday Future Intelligent Electric Inc. (FFIE) fell 1.1% to $0.0456 on volume of 28,670,184 shares Emergent Biosolutions Inc. (EBS) rose 67.7% to $3...
REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the quarter ended March 31, 2024. Rec...